IFNB1 and COVID-19: It is difficult to explain this result, but it might be related to the toxicity (e.g., gastrointestinal mucosal damage) in the case of colchicine treatment.[93] In addition, it is possible that the use of IFN-β in combination with SOC was associated with increased TEAEs in treating severe COVID-19, which should be weighed in all future IFN-β studies.[94]